14-day Premium Trial Subscription Try For FreeTry Free

Vir Biotechnology, Inc. Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -12.44. In total, the insiders bought 6 543 698 and sold 8 941 068 VIR shares in the last 100 trades.

Insider Power

(Last 100 transactions)
-12.44
Buy 6 543 698 Shares
Sell 8 941 068 Shares

Historical Insider Trades

Date Type Action Person Amount
Jun 12, 2024 Common Stock Sell De Backer Marianne 53 118
Jun 12, 2024 Common Stock Buy De Backer Marianne 53 118
Jun 11, 2024 Common Stock Sell Ramasastry Saira 4 000
Jun 03, 2024 Common Stock Buy Eisner Mark 0
May 30, 2024 Common Stock Buy Sigal Charles Elliott 8 000
May 30, 2024 Stock Option (Right to Buy) Buy Sigal Charles Elliott 16 000
May 30, 2024 Common Stock Buy Scangos George A 8 000
May 30, 2024 Stock Option (Right to Buy) Buy Scangos George A 16 000
May 30, 2024 Common Stock Buy Sato Vicki L 8 000
May 30, 2024 Stock Option (Right to Buy) Buy Sato Vicki L 16 000
May 30, 2024 Common Stock Buy Ramasastry Saira 8 000
May 30, 2024 Stock Option (Right to Buy) Buy Ramasastry Saira 16 000
May 30, 2024 Common Stock Buy Nelsen Robert 8 000
May 30, 2024 Stock Option (Right to Buy) Buy Nelsen Robert 16 000
May 30, 2024 Common Stock Buy Napolitano Janet 8 000
May 30, 2024 Stock Option (Right to Buy) Buy Napolitano Janet 16 000
May 30, 2024 Common Stock Buy More Robert J 8 000
May 30, 2024 Stock Option (Right to Buy) Buy More Robert J 16 000
May 30, 2024 Common Stock Buy Hatfield Jeffrey S. 8 000
May 30, 2024 Stock Option (Right to Buy) Buy Hatfield Jeffrey S. 16 000
May 29, 2024 Common Stock Buy Farid Ramy 16 000
May 29, 2024 Stock Option (Right to Buy) Buy Farid Ramy 16 000
May 29, 2024 Common Stock Buy Farid Ramy 0
May 29, 2024 Common Stock Buy Bischofberger Norbert W 16 000
May 29, 2024 Stock Option (Right to Buy) Buy Bischofberger Norbert W 16 000
Click to get the best stock tips daily for free!

About Vir Biotechnology, Inc.

Vir Biotechnology. Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.... VIR Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT